CLYM
Climb Bio Inc
NASDAQ: CLYM · HEALTHCARE · BIOTECHNOLOGY
$8.88
+1.14% today
Updated 2026-04-30
Market cap
$436.60M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.88
Dividend yield
—
52W range
$1 – $10
Volume
0.6M
Climb Bio Inc (CLYM) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-36.8%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
-100.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-1.3%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
-4.7%
2025-11-06
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-09 | $-0.26 | -38.9% | $7.18 | $7.33 | +2.1% |
| 2025-11-06 | $-0.19 | -29.5% | $1.92 | $1.83 | -4.7% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.19 | $-0.26 | -38.9% | — | — |
| 2025-09-30 | $-0.15 | $-0.19 | -29.5% | — | — |
| 2025-06-30 | $-0.18 | $-0.13 | +27.8% | — | — |
| 2025-03-31 | $-0.15 | $-0.31 | -106.7% | — | — |
| 2024-12-31 | $-0.15 | $-0.13 | +13.3% | — | — |
| 2024-09-30 | — | $-0.13 | — | — | — |
| 2024-06-30 | — | $-1.81 | — | — | — |
| 2024-03-31 | — | $-0.06 | — | — | — |
| 2023-12-31 | $-0.13 | $-0.13 | -1.1% | — | — |
| 2023-09-30 | $-0.14 | $-0.15 | -4.7% | — | — |
| 2023-06-30 | $-0.16 | $-0.19 | -21.6% | — | — |
| 2023-03-31 | $-0.84 | $-0.84 | +0.0% | — | — |
| 2022-12-31 | $-0.33 | $-0.29 | +12.1% | — | — |
Frequently asked questions
Has Climb Bio Inc beaten earnings estimates?
Climb Bio Inc has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of -36.8% over the last 4 quarters.
How does CLYM stock react to earnings?
CLYM stock has moved an average of -1.3% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.